- Home
- CELC vs ESPR Comparison
CELC vs ESPR Comparison
Compare CELC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- ESPR
- Stock Information
- Founded
- CELC 2011
- ESPR 2008
- Country
- CELC United States
- ESPR United States
- Employees
- CELC N/A
- ESPR N/A
- Industry
- CELC Medical Specialities
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CELC Health Care
- ESPR Health Care
- Exchange
- CELC Nasdaq
- ESPR Nasdaq
- Market Cap
- CELC 327.3M
- ESPR 305.0M
- IPO Year
- CELC 2017
- ESPR 2013
- Fundamental
- Price
- CELC $10.15
- ESPR $0.80
- Analyst Decision
- CELC Strong Buy
- ESPR Buy
- Analyst Count
- CELC 6
- ESPR 7
- Target Price
- CELC $30.17
- ESPR $5.93
- AVG Volume (30 Days)
- CELC 190.9K
- ESPR 5.1M
- Earning Date
- CELC 05-14-2025
- ESPR 05-06-2025
- Dividend Yield
- CELC N/A
- ESPR N/A
- EPS Growth
- CELC N/A
- ESPR N/A
- EPS
- CELC N/A
- ESPR N/A
- Revenue
- CELC N/A
- ESPR $259,574,000.00
- Revenue This Year
- CELC N/A
- ESPR $5.70
- Revenue Next Year
- CELC N/A
- ESPR N/A
- P/E Ratio
- CELC N/A
- ESPR N/A
- Revenue Growth
- CELC N/A
- ESPR 12.99
- 52 Week Low
- CELC $7.58
- ESPR $0.82
- 52 Week High
- CELC $19.77
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- CELC 46.58
- ESPR 32.43
- Support Level
- CELC $9.64
- ESPR $0.93
- Resistance Level
- CELC $10.80
- ESPR $1.11
- Average True Range (ATR)
- CELC 0.66
- ESPR 0.11
- MACD
- CELC -0.06
- ESPR 0.01
- Stochastic Oscillator
- CELC 25.25
- ESPR 17.93
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.